beximco and renata

26
Introduction Origin The following financial report analysis is based on three companies- Beximco Pharma, Square Pharmaceuticals Limited and Renata Limited. All these three companies are well known pharmaceuticals companies in the today’s market of Bangladesh. This report is prepared for Mrs. Dilara Afroz Khan (DAK), instructor of the course FIN 254 (Introduction to Financial Management) for the fall semester 2006 as a partial requirement of the course. Objective The objective of this report is to analyze the scenario of these three companies as well as gathering practical knowledge from the financial context and establish a relation with our knowledge of the course. A key objective is to conduct a ratio analysis, developing common size income statement of the companies and evaluate their performances by generating industry averages or industry standard values. To evaluate their performances against the industry standard values we have used the Do Pont System to analyze the ratios. The project includes application of various ratio formulas to find out the ratios required to understand the financial situation of the companies in comparison to the industry average. 1

Upload: nasef-mohd

Post on 06-Dec-2015

227 views

Category:

Documents


3 download

DESCRIPTION

Pharmaceuticals industry in Bangladesh

TRANSCRIPT

Page 1: Beximco and Renata

Introduction

Origin

The following financial report analysis is based on three companies- Beximco Pharma, Square

Pharmaceuticals Limited and Renata Limited. All these three companies are well known

pharmaceuticals companies in the today’s market of Bangladesh. This report is prepared for Mrs.

Dilara Afroz Khan (DAK), instructor of the course FIN 254 (Introduction to Financial Management)

for the fall semester 2006 as a partial requirement of the course.

Objective

The objective of this report is to analyze the scenario of these three companies as well as

gathering practical knowledge from the financial context and establish a relation with our

knowledge of the course. A key objective is to conduct a ratio analysis, developing common size

income statement of the companies and evaluate their performances by generating industry

averages or industry standard values. To evaluate their performances against the industry

standard values we have used the Do Pont System to analyze the ratios. The project includes

application of various ratio formulas to find out the ratios required to understand the financial

situation of the companies in comparison to the industry average.

Methodology

Before gathering all the information, we generated a clear and precise strategy to work. First we

collected the Annual report of the companies for the year 2005. Then the ratios and industry

standard values are generated using ‘Microsoft Excel’. Afterwards, the original reports are

common sized using the format of our book (Principles of Managerial Finance,

Lawrence J.Gitman). Finally, through implementing our learning in the course, the analysis

part was done.

1

Page 2: Beximco and Renata

Scope

This report focuses on the various ratios under the criterion of liquidity, profitability, asset

management, debt management, market value which are generated on the financial

performances of the Pharmaceuticals Companies naming- “Beximco Pharma, Square

Pharmaceuticals Limited and Renata Limited” from Dhaka Stock Exchange of the year 2005.

Limitation

The contents of the report are exclusively obtained from the annual reports and our learning in

the course FIN 254. Therefore, the analysis part reflects our limited knowledge about the vast

financial world. Furthermore, the assumptions made about various situations can be different

from what it is in the real world. So, the content of the report may vary slightly from reality and the

analysis in the report may not fully reflect the actual situation of the companies.

Source of Data

The information provided in this report was collected in several ways. We collected the annual

report from people in parental level and other essential information was collected from the

Internet. Finally, they were manipulated with the help of the contents of our book.

2

Page 3: Beximco and Renata

Backgrounds of the Companies

In today’s market of Bangladesh Beximco Pharma, Square Pharmaceuticals Limited and Renata

Limited are well reputed and well recognized companies. In addition, all these three companies

are among the leading companies of the pharmaceuticals market and they are doing good

business in the market race.

Beximco Pharma is a leading Edge pharmaceuticals company based in Dhaka, Bangladesh. It is

also acclaimed for its outstanding product quality, world class manufacturing facilities, product

development capabilities and outstanding professional services. Their mission is that each of their

activities must benefit and add value to the common wealth of the society.

Square Pharmaceuticals Limited is another leading company of Bangladesh. They view business

as a means to the material and social wellbeing of the investors, employees and the society at

large, leading to accretion of wealth through financial and moral gains as a part of the process of

the human civilization. Their vision, there mission and their objectives are to emphasize on the

quality of product, process and services leading to growth of the company imbibed with good

governance practices.

Like others Renata Limited is also a renowned company of Bangladesh. Their mission is to

produce and provide quality & innovative healthcare relief for people, maintain stringently ethical

standard in business operation also ensuring benefit to the shareholders, stakeholders and the

society at large. Their objectives are to conduct transparent business operation based on market

mechanism within the legal & social framework with aims to attain the mission reflected by our

vision.

3

Page 4: Beximco and Renata

Why we have chosen the company

Beximco Pharma, Square Pharmaceuticals Limited and Renata Limited – all these three

companies have a real hold in the market. So choosing these companies will provide closer

scenario of the practical and actual situations. Naturally, all these companies perform various

kinds of financial activities each year. So we will be able to focus on various parts and terms more

appropriately. Moreover, this will help a lot to enrich our acquired knowledge.

These are the reasons why we have chosen Beximco Pharma, Square Pharmaceuticals Limited

and Renata Limited to prepare the report.

4

Page 5: Beximco and Renata

RATIO CALCULATIONS

Workings:

All the calculations are done for the ratio shown in below:

Liquidity Ratios

1. Liquidity Ratio = Current Asset/Current Liabilities (Current Asset and Current Liabilities

are taken from balance sheet)

2. Quick or Acid Ratio = Current Asset-Inventories/Current Liabilities (Current Asset,

Inventories, Current Liabilities are taken from balance sheet)

Activity or Asset Management Ratios

3. Inventory Turnover = Cost of Good Sold/Inventory (COGS is taken from income

statement, and Inventory from balance sheet)

4. Fixed Asset Turnover = Cost of Good Sold/Fixed Asset (COGS is taken from income

statement and Fixed Asset from balance sheet)

5. Total Asset Turnover = Total Operating Income/Total Asset (Total Operating Income Total

Asset is taken from income statement and Total Asset from balance sheet)

6. Average collection period (period average) = Accounts receivable/Average sales per day .

Ө [Average sales per day = Annual sales/ 360]

7. Average payment period (period end) = Accounts payable/ Average purchases per Day.

Ө [Average purchases per day = Annual purchases/ 360]

5

Page 6: Beximco and Renata

Debt Management Ratios

7. Debt Ratio = Total Liabilities/ Total Asset (Total Liabilities, Total Asset are taken from

balance sheet)

8. Times Interest Earned = EBIT/Interest paid on borrowing (EBIT, and Interest are taken

from Income sheet)

9. Fixed payment coverage = EBIT + Lease payment/ Interest + Lease payments +

{(principal payments + Preferred stock dividends) * [1/(1-T)]}

Profitability Ratios

10. Gross Profit Margin = Sales – Cost of goods sold/ Sales (Sales or Turn over and Cost of

goods sold are taken from Income statement)

11. Operating Profit Margin = Operating Profits / Sales (Sales and Operating Profits are taken

from Income statement)

12. Net Profit Margin = Earnings Available for Common stockholders/ Sales (Sales and

Earnings available for common stockholders are taken from Income Statement)

13. Earnings per Share = Earnings Available for common stockholders/ Numbers of Shares of

common stock outstanding. (EACSH is from income statement and No. Of common stock

is from Balance sheet)

14. Return On Total Assets = Earnings Available for common stockholders /Total Assets

(EACSH is taken from Income sheet and Total Asset is taken from balance sheet)

15. Return On Equity = Earnings Available for common stockholders /Common Stock Equity

(EACSH is taken from Income sheet and Common stock Equity is taken from balance

sheet)

Market Value Ratios

16. Price/Earnings Ratio = Market Price Per Share of common stock / Earnings Per Share

(Price Per Share taken from News paper and EPS from Income statement)

17. Market/Book Ratio = Market/Book = Common Stock Equity / Number of Shares of

Common Stock Outstanding (Number of Shares of Common Stock Outstanding = Total

Common Equity / num of Shares where Total Common Equity is taken from balance

sheet)

6

Page 7: Beximco and Renata

Ratio BEXIMCO SQUARE RENATA

Industry

Average

   

Liquidity  

Current Ratio 1.40 1.78 1.75 1.64

Quick Ratio 0.72 1.19 0.74 0.88

   

Activity  

Inventory Turnover 1.05 2.63 2.13 1.94

Average Collection Period 84.38 14.67 36.31 45.12

Average Payment Period 92.83 7422.43 103.74 2539.67

Total Asset Turnover 0.30 0.76 1.26 0.78

   

Debt  

Debt Ratio 0.38 0.31 0.39 0.36

Times Interest Earned Ratio 3.26 11.30 13.78 9.45

Fixed-Payment Coverage Ratio 2.54 3.65 5.82 4.00

   

Profitability  

Gross Profit Margin 0.47 0.36 0.48 0.44

Operating Profit Margin 0.22 0.22 0.20 0.21

Net Profit Margin 0.15 0.16 0.12 0.14

Earnings Per Share (EPS) 6.36 234.67 239.71 160.25

Return On Total Assets (ROA) 0.04 0.13 0.15 0.11

Return On Common Equity

(ROE) 0.09 0.27 0.25 0.20

   

Market  

Price/Earnings (P/E) Ratio 9.09 0.40 0.42 3.30

Market/Book (M/B) Ratio 0.83 0.11 0.11 0.35

7

Page 8: Beximco and Renata

RATIO ANALYSIS

Liquidity Ratios

The liquidity of a firm is measured by its ability to satisfy short-term obligations. Two basic

measures are Current and Quick ratio.

Current Ratio

The current ratio measures the firm’s ability to meet its short-term obligations. The higher a firm’s

current ratio, the more liquid a firm is considered to be.

The industry average for the three pharmaceuticals companies is 1.64.

For Beximco Pharma, we found that, current assets recorded Tk.3495849163, and current

liabilities of Tk.2501824568. Thus the current ratio calculated is 1.40. Compared to industry

average, liquidity of Beximco Pharma is little bit low. This indicates problem within the company’s

cash management system.

For Square Pharmaceuticals Limited, we found that, current assets recorded Tk.4031684955,

and current liabilities of Tk.2260755481. Thus the current ratio calculated is 1.78. Compared to

the industry average, Square Pharmaceuticals Limited is very liquid. Still it’s higher from the

industry average, so the company may hold excessive cash, account receivable or inventory.

For Renata Limited, we found that, current assets recorded Tk.672355277, and current liabilities

of Tk.384140329. Thus the current ratio calculated is 1.75. Compared to industry average, the

liquidity is good enough. That means company’s cash management system is working good.

Quick (Acid-Test) Ratio

Inventory is excluded in calculating quick ratio. The quick ratio provides a better measure of

liquidity when a firm’s inventory cannot be easily converted into cash.

The industry average is 0.88.

Inventory for Beximco Pharma account for Tk.1683722059, and the quick ratio calculated is thus

0.72. It is quite low from the industry average. This indicates low current assets and problems for

the company.

Inventory for Square Pharmaceuticals Limited account for Tk.1342365478, and the quick ratio

calculated is thus 1.19. It is quite over the industry average though the stock of inventory is very

high. As a pharmaceuticals company it seems quite good.

8

Page 9: Beximco and Renata

Inventory for Renata Limited account for Tk.388384007, and the quick ratio calculated is thus

0.74. It is also quite low from the industry average. That means company is not running smoothly.

Activity Ratios

Activity ratios measure the speed with which various accounts are converted into sales or cash-

inflows or outflows

Inventory Turnover

Inventory turnover commonly measures the activity, or liquidity, of a firm’s inventory.

The industry average for textile mills in Bangladesh is 1.94.

For Beximco Pharma, Cost of Goods Sold is Tk.1768522363. So, inventory turnover is 1.05. As it

is lower than the industry average, so the inventory management of the company is not working

well.

For Square Pharmaceuticals Limited, Cost of Goods Sold is Tk.3525402669. So, inventory

turnover is 2.63. As it is more than the industry average, the firm is operating fairly. But still the

company may have lower level of inventory which may cause stock outs and lost sales.

For Renata Limited, Cost of Goods Sold is Tk.829197436. So, inventory turnover is 2.13. So it is

also higher than the industry average. This indicates company’s operations are working smoothly

but they may have lower level of inventory.

Average Collection Period

The average collection period is useful in evaluating credit and collection policies.

The industry average is 45.12

For Beximco Pharma, the accounts receivable is Tk.779798943, and an average sale per day is

Tk.9241729.372. So, average collection period is 84.38 days. This is much over the industry

average. The company could lose opportunities for investment in the delayed days.

For Square Pharmaceuticals Limited, the accounts receivable is Tk.288732137, and an average

sale per day is Tk.19682092.08. So, average collection period is 14.67 days. This is lower than

the industry average. This may shows good accounts receivable management but it also shows

strictness on the payers that may create problems in future.

9

Page 10: Beximco and Renata

For Renata Limited, the accounts receivable is Tk.162224078, and an average sale per day is

Tk.4468210.664. So, average collection period is 36.31 days. This is also lower than the industry

average. So, the company may be little bit strict to the payers.

Average Payment Period

This ratio shows how quickly the firm is paying of its debts.

The industry average is 86.01 days.

For Beximco Pharma, the accounts payable is Tk.271922585, and an average purchase per day

is Tk.2929188.397. So, average payment period is 92.83 days. This is way beyond the industry

average. Company could be facing interest on the payables.

For Square Pharmaceuticals Limited, the accounts payable is Tk.528180353, and an average

purchase per day is Tk.8594147.428. So, average payment period is 61.46 days. This is lower

than the industry average. So, it indicates good accounts payable management but still the

company is losing the benefits of paying later and investing in other activities.

For Renata Limited, the accounts payable is Tk.43799293, and an average purchase per day is

Tk.422184.3444. So, average payment period is 103.74 days. This is also over the industry

average. So, company could be facing interest on the payables.

Total Asset Turnover

Total asset turnover indicates the efficiency with which the firm uses its assets to generate sales.

The industry average counts for 0.78.

For Beximco Pharma the total asset turnover was 0.30. Compared to the industry average it is

quite low. So, the company’s failed to use its assets efficiently.

For Square Pharmaceuticals Limited the total asset turnover was 0.76. It is close to the industry

average. So, the company uses its assets effectively but it can be done more appropriately.

For Renata Limited the total asset turnover was 1.26. Compared to the industry average it is quite

well. So, the company’s assets have been efficiently used.

Debt Ratios

It indicates the amount of other people’s money being used to generate profits.

10

Page 11: Beximco and Renata

Debt Ratio

This ratio measures the proportion of total assets financed by the firm’s creditors.

The industry average for Bangladesh textile industry is 0.36.

Debt Ratio for Beximco Pharma is 0.38. It is close to the industry average but still higher. The

firm thus has a high degree of indebt ness and more financial leverage

Debt Ratio for Square Pharmaceuticals Limited is 0.31. It is lower than the industry average. This

indicates that the company has financed a low portion of its assets with its debt. Thus the

company has more scope to look for funds from investors.

Debt Ratio for Renata Limited is 0.39. It is also higher than the industry average but close to it.

Infact, this company has more debts compared to other firms.

Times Interest Earned Ratio

The times interest earned ratio measures the firm’s ability to make contractual interest payments.

The industry average is calculated 9.45.

For Beximco Pharma the ratio is 3.26. It is lower than the industry average. This indicates less

capability of meeting the interest of the company.

For Square Pharmaceuticals Limited the ratio is 11.30. This is higher than the industry average.

So, the company is able to meet its interest.

For Renata Limited the ratio is 13.78. Compared to the industry average and the other

companies, Renata Limited is quite better off and quite able to meet its interests.

Fixed Payment Coverage Ratio

The fixed payment coverage ratio measures the firm’s ability to meet all fixed payment

obligations, such as loan interest and principal, lease payments and preferred stock dividends.

The industry average is 4.00.

For Beximco Pharma the ratio is 2.54. It is lower than the industry average. Compared to other

companies this company is rather than risky to invest.

For Square Pharmaceuticals Limited the ratio is 3.65. It is closer to the average but still lower. So,

little bit risk is still remaining.

For Renata Limited the ratio is 5.82. Compared to the industry average the ratio is quite good.

Comparatively there is a low risk for owners and lenders in Renata Limited.

11

Page 12: Beximco and Renata

Profitability Ratios

There are many measures of profitability. As a group these measures enable the analyst to

evaluate firm’s profits with respect to a given level of sales, a certain level of assets, or the

owner’s investment.

Gross Profit Margin

The Gross Profit Margin measures the percentage of each sales taka remaining after the firm has

paid for its goods

The industry average is 44%

Beximco Pharma has a margin of 47%. It is higher than the industry average. This high

percentage reflects a relatively low cost of goods sold.

Square Pharmaceuticals Limited has a margin of 36%. This high percentage reflects a relatively

low cost of goods sold.

Renata Limited has a margin of 48%. This is also higher than the industry average. It indicates

low cost of goods sold.

Operating Profit Margin

The operating profit margin measures the percentage of each sale taka remaining after all costs

and expenses other than interest, taxes and preferred stock dividends are deducted.

The industry average is 21%.

The operating profit margin for Beximco Pharma is 22%. This is higher than the average. So, the

company is running good operating profit.

The operating profit margin for Square Pharmaceuticals Limited is 22%. So, the company is also

running good operating profit.

The operating profit margin for Renata Limited is 20%. It is lower than the industry average. So,

the company should look for more profit.

Net Profit Margin

The net profit margin measures the percentage of each sales taka after all costs and expenses.

High percentage is always preferable.

The industry average is 14%.

12

Page 13: Beximco and Renata

The net profit margin for Beximco Pharma is 15%. This is higher than the average. So, the

company seems to be quite profitable.

The net profit margin for Square Pharmaceuticals Limited is 16%. This is higher than the average.

Comparing to other companies, it profits more.

The net profit margin for Renata Limited is 12%. This is lower than the average. So, the company

should look for more profit.

Earning Per Share (EPS)

EPS is a very important fact for any financial report. It represents the number of taka earned

during the period on behalf of each outstanding share of common stock.

The industry average is 160.25

EPS for Beximco Pharma is 6.36. This is much less than the industry average. This company in a

bad shape and has very few scope of attracting more stockholders

EPS for Square Pharmaceuticals Limited is 234.67. This company has a high EPS thus showing

more potential on profits per stock.

EPS for Renata Limited is 239.71. It is more than the average. So, it is showing more potential on

profits per stock.

Return on Total Assets (ROA)

This ratio measures the overall effectiveness of management in generating profits with its

available assets. The higher a firms return on total assets, the better for the company.

The industry average is 11%.

ROA for Beximco Pharma is 4%. It is lower than the average. So, the return is less for this

company.

ROA for Square Pharmaceuticals Limited is 13%. So, it provides higher returns on assets.

ROA for Renata Limited is 15%. It is higher than the average which indicates higher return on

assets compared to other companies.

Return on Common Equity (ROE)

This ratio measures the return earned on the common stock holder’s investment in the firm. The

higher this return, the better off is the owners.

The industry average is 20%.

13

Page 14: Beximco and Renata

ROE for Beximco Pharma is 9%. It is lower than the average. This company’s high return on

equity suggests great profitability.

ROE for Square Pharmaceuticals Limited is 27%. So, it provides higher returns on assets.

ROE for Renata Limited is 25%. It is higher than the average. So, it has greater profitability.

Market Ratios

Market ratios relate a firm’s market value, as measured by its current share price, to certain

accounting values.

Price/Earning Ratio (P/E)

This ratio is commonly used to measure the amount that the investors are willing to pay for each

taka of the firm’s earnings.

The industry average is 3.30

The ratio for Beximco Pharma is 9.09. It means that the investors were paying 9.09 TK for each 1

TK of earnings.

The ratio for Square Pharmaceuticals Limited is 0.40. It means that the investors were paying

0.40 TK for each 1 TK of earnings.

The ratio for Renata Limited is 0.42. It means that the investors were paying 0.42 TK for each 1

TK of earnings.

Market/Book (M/B) Ratio

This ratio provides an assessment of how investors view the firm’s performance.

The industry average is 0.35

The ratio for Beximco Pharma is 0.83. This is higher than the average. So, the investor expects

more from this company.

The ratio for Square Pharmaceuticals Limited is 0.11. It’s less from the average. So, expiation

decreases.

The ratio for Renata Limited is 0.11. This is also less than average and so expectation also

deceases.

Common Size Income Statement

         

14

Page 15: Beximco and Renata

  Common-Size Income Statements    For Pharmaceutical Companies  

 For The Year Ended December 31,

2005          Beximco Square Renata     Sales revenue 100.00% 100.00% 100.00%  Less: Cost Of Goods Sold (COGS) 53.16% 49.75% 51.55%  Gross Profit Margin 46.84% 36.19% 48.45%     Less: Operating Expenses 25.07% 13.89% 29.80%  Selling Expense 21.49% 11.26% 16.39%  General And Administrative expenses 3.33% 2.39% 13.11%  Depreciation Expense 0.25% 0.23% 0.30%  Total Operating Expenses 25.07% 13.89% 29.80%  Operating Profit Margin 21.77% 22.30% 19.70%     Less: Interest expense 6.67% 1.97% 1.43%  Net Profit Before taxes 14.59% 21.64% 17.37%  Less: Taxes 0.12% 5.18% 5.40%  Net Profit After taxes 14.71% 16.45% 11.97%  Less: Preferred stock dividends 1.03% 2.87% 1.00%  Net Profit Margin 13.67% 13.58% 10.97%           

DU PONT SYSTEM

15

Page 16: Beximco and Renata

Relate ROA and ROE

ROA = Earnings available to common stockholder/ Total Asset

= (Earnings available to common stockholder/ sales) * (Sales / Total Asset)

= Net Profit Margin * Total Asset Turnover

ROE = Earnings Available to common stockholder/ Common stock Equity

= (Earnings available to common stockholder/ Total Asset) * (Total Asset/ Common

stock Equity)

= ROA * FLM (Financial Leverage multiplier)

Analysis

Beximco Pharma

ROE (9%) = ROA (4%) * FLM (2.25)

A low ROE that results from a low ROA reflects significant problem in the total asset turnover.

Comparing it with the industry average we can conclude a major problem of sales.

Square Pharmaceuticals Limited

ROE (27%) = ROA (13%) * FLM (2.08)

16

Page 17: Beximco and Renata

Though ROE and ROA is quite better off compared to the industry, ROA is quite low compared to

other profitable companies. This suggests a problem in total asset turnover, which indicates a

huge stock of assets. The company is in stocking more assets than they require.

Renata Limited

ROE (25%) = ROA (15%) * FLM (1.67)

A comparatively low ROA points out low net profit margin. This is the result of low earnings

available for common stock holders and sales compared to other profitable companies.

CONCLUSION

17

Page 18: Beximco and Renata

Beximco, Square Pharmaceuticals and Renata are three of the most popular companies in the

pharmaceutical industry of Bangladesh. By carrying out a ratio analysis of these companies, we

ere able to get an inside overview of the operation of the firm and match them with their

reputation. Clearly each company is distinct in setting their operation policies and matching the

expectations of the stockholders. There are still many changes to hope for in these companies as

time puts new challenges in front of them.

Suggestions

18

Page 19: Beximco and Renata

After completing the analysis part we have recommended some suggestions, which they may follow:

1. Beximco Pharma should try and increase its quality and thus increase sales. Beximco

Pharma policies should be considered to increase ROE and thus attract more stockholders.

2. Asset management of Square Pharmaceuticals Limited should be improvised to meet the

requirements. This will help them to solve their problems.

3. Company should focus in increasing their sales and earnings available to common stock

holders.

What we have learned from this

project

Nothing goes completely with books. Infact, practical scenario is naturally much more

complicated. In the future, when we will enter the commercial life, we have to relate our

knowledge with the practical scenario. This project is opportunity to practice such kind of

activities. This project gave us an opportunity to learn several important aspects about the finance

of a company. Through this project we have learned several financial processes like how to

prepare common size income statement and calculate ratios from the figures of the company’s

balance sheet and income statement. We have also learned to evaluate financial ratios to analyze

and monitor a firm’s performance. Thus we succeed to relate the practical scenario with the

contents of our textbook.

19